ClinicalTrials.gg
CompletedNCT06945419Updated Aug 19, 2026

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

A Phase 1 interventional study of LY4086940 and Placebo in Healthy, Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Enrollment
64th of 117
219 · median 267
Started
2025
with 27 others
Phase 1
40 of 118
8 open now
Registered
75th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 64th largest by enrollment of the 117 interventional ones that give a count, is one of 28 that started in 2025, is one of 40 in phase 1, and was the 75th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.

Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.

03

Conditions studied

  • Healthy
  • Overweight
  • Obesity
  • Type 2 Diabetes

Keywords

  • Oral
  • Incretin
  • Weight loss
  • Overweight
  • Obesity
  • Diabetes
04

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 219 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have no significant body weight change for the 3 months prior to screening

Part A and Part E:

  • Are considered healthy
  • Have a (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening

Part B:

  • Have a BMI of 27 to 45 kg/m2 at screening

Part C:

  • Have a BMI of 25 to 45 kg/m2 at screening

Part D:

  • Have type 2 diabetes
  • Have (HbA1c) ≥6.5% and ≤10.5% at screening
  • Have a BMI of 27 to 45 kg/m2 at screening

Exclusion criteria

Exclusion Criteria:

  • Have had an acute cardiovascular condition within the past 6 months prior to screening
  • Have liver disease or pancreatitis
  • Have used medications for weight loss within the 3 months prior to screening

Parts A, B, C, E:

  • Have any form of diabetes

Part D:

  • Have type 1 diabetes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Part A: LY4086940 Single Dose (Healthy Participants)

    Participants will receive a single dose of LY4086940 orally

    Drug: LY4086940

  • Placebo comparator
    Part A: Placebo Single Dose (Healthy Participants)

    Participants will receive a single dose of placebo orally

    Drug: Placebo

  • Experimental
    Part A: LY4086940 Multiple Dose (Healthy Participants)

    Participants will receive LY4086940 orally for 3 days

    Drug: LY4086940

  • Placebo comparator
    Part A: Placebo Multiple Dose (Healthy Participants)

    Participants will receive placebo orally for 3 days

    Drug: Placebo

  • Experimental
    Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity)

    Participants will receive LY4086940 orally for 4 weeks

    Drug: LY4086940

  • Placebo comparator
    Part B: Placebo Multiple Dose (Participants with Overweight or Obesity)

    Participants will receive placebo orally for 4 weeks

    Drug: Placebo

  • Experimental
    Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity)

    Participants will receive LY4086940 orally for 4 weeks

    Drug: LY4086940

  • Placebo comparator
    Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity

    Participants will receive placebo orally for 4 weeks

    Drug: Placebo

  • Experimental
    Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity)

    Participants will receive LY4086940 orally for 4-6 weeks

    Drug: LY4086940

  • Placebo comparator
    Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity)

    Participants will receive placebo orally for 4-6 weeks

    Drug: Placebo

  • Experimental
    Part E (Open-Label): LY4086940 Single Dose (Healthy Participants)

    Participants will receive a single dose of LY4086940 intravenously (IV)

    Drug: LY4086940

Interventions

  • DrugLY4086940

    Administered orally

  • DrugPlacebo

    Administered orally

  • DrugLY4086940

    Administered IV

07

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline up to Week 9

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4086940

    Time frame: Predose up to Day 64

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY4086940

    Time frame: Predose up to Day 64

08

Study locations

5 sites
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33172, United States
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Aug 2026, 15 months.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2025
First posted
Apr 25, 2025
StartActual
Apr 23, 2025
Primary completionActual
Aug 5, 2026
CompletionActual
Aug 5, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06945419
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
Apr 23, 2025
Primary completion
Aug 5, 2026
Completion
Aug 5, 2026
Last update
Aug 19, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion